Company intelligence / Profile preview

Ribological

Mainz, Rhineland-Palatinate, Germany
Ownership
Private
Development stage
Other
01

Overview

Ribological collaborated with 4SC Discovery and Crelux to develop synergistic small molecules with their RNA-based immunotherapies for cancer. Preclinical testing was planned, though no recent clinical results exist or have been reported publicly[2][3].

Therapeutic areas
Oncology
Modalities
RNA therapySmall molecule
Industry
Biotech
02

Partnerships

4SC DiscoveryCrelux

Beyond the preview

Go deeper on Ribological.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ribological.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call